Developer docs
API playgroundTry for free, no card

Search company profiles

Instem

Full company profile

uuid0003ww5

Namestring
Instem
Legal namestring
Instem
Websiteurl
instem.com
Company typeenum
Private
Founded yearint
1969
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersConshohocken, United States
HQ citystring
Conshohocken
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical study management, regulatory submission software, predictive toxicology software, laboratory information systems, clinical trial analytics
Industry4 codes
1Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
CodeHLAGAJAMPrimaryYes
2Data Management, Biostatistics & Statistical Programming FSP
CodeHLAGAOABPrimaryNo
3Quality Assurance, GxP Compliance & Auditing FSP
CodeHLAGAOAEPrimaryNo
4Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
CodeHLAGAKALPrimaryNo
NAICS code4 codes
  • Professional, Scientific, and Technical Services54
  • Other Scientific and Technical Consulting Services54169
  • Computer Systems Design Services541512
  • Management, Scientific, and Technical Consulting Services5416
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Engineering, Accounting, Research, Management8700
Product category
Life Sciences R&D Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1SaaS Software Subscriptions
TypeSubscription Recurring
Description

Instem generates revenue primarily through SaaS subscription licensing of its software platforms including Leadscope, Provantis, BioRails, Matrix Gemini LIMS, and Clinical Trial Analytics solutions. Annual and multi-year subscription contracts with enterprise customers.

instem.com
2Professional Services
TypeProfessional Services
Description

Instem Catalyst provides scientific and regulatory consulting services including strategy and advisory, implementation and modernization, validation and compliance, adoption and optimization, and resourcing/managed services.

instem.com
3SEND Services
TypeProfessional Services
Description

SEND Advantage Services including SEND Deliver, SEND Comply, SEND Advise, SEND Warehousing, and SEND Source for SEND data conversion and compliance services.

instem.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise SaaS subscription model
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed

instem.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 14 records shown
1Leadscope
Description

In silico predictive toxicology platform including Leadscope Model Applier, Predict, KnowledgeScan, Centrus, and Advance solutions

instem.com
+13 more records
Core offering1 text field

Instem is a global SaaS provider for life sciences R&D, offering an integrated portfolio spanning in silico & data insights (Leadscope predictive toxicology), preclinical study management (Provantis, BioRails, Climb), regulatory submission (SEND Advantage Services, Submit), lab execution (Matrix Gemini LIMS), and clinical trial analytics (Accel, Aspire, Blur via d-wise). The company sells subscription-based software platforms and supporting professional services to pharmaceutical, biotech, CRO, CDMO, academic, and agrichemical organizations across 700+ clients globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 75% reduction in setup time and 45% reduction in study design time
Product overview1 text field

Instem is a global SaaS provider for life sciences R&D offering an integrated platform of solutions across In Silico & Data Insights, Study Management, Regulatory Submission, Lab Execution, and Clinical Trial Analytics. The portfolio includes core products such as Leadscope Model Applier, Predict, KnowledgeScan, Centrus, and Advance for predictive toxicology and data insights; Provantis, BioRails, Climb, Morphit, and Pristima for study management; SEND Advantage Services and Submit for regulatory submissions; Matrix Gemini LIMS for lab execution; and Accel, Aspire, Blur, and CTT Services for clinical trial analytics through d-wise (an Instem company). The company serves over 700 clients including pharmaceutical, biotech, CRO, CDMO, academic research, and agrichemical organizations. Founded in 1969, Instem has grown through acquisitions including RockStep Solutions, Xybion, and Autoscribe Informatics.

Product and service19 records
1Leadscope Model Applier
CategoryIn Silico & Data Insights
Description

Predictive QSAR modeling platform delivering accurate predictions for wide-ranging toxicological endpoints, driven by regulatory guidelines, enabling early risk assessments and reducing reliance on traditional animal testing.

2Predict
CategoryIn Silico & Data Insights
Description

Expert In Silico toxicology support service delivering a wide range of reports with proven regulatory acceptance for early-stage safety assessments.

3KnowledgeScan
CategoryIn Silico & Data Insights
Description

Technology-enabled Target Safety Assessment service that aggregates proprietary and public data, providing comprehensive insights into potential toxicological risks for faster data-driven decisions.

4Centrus
CategoryIn Silico & Data Insights
Description

Advanced Translational Safety Solution enabling data alignment, review, and visualizations from diverse sources for high-quality data management and seamless data sharing.

5Advance
CategoryIn Silico & Data Insights
Description

Expert-led S1B Weight of Evidence (WoE) assessment service evaluating carcinogenicity risks, supporting ICH S1B guidelines and accelerating development timelines.

6Climb
CategoryStudy Management
Description

Cloud-based preclinical in vivo data capture platform enabling capture from any therapeutic area to accelerate studies, with 75% reduction in setup time demonstrated.

7Provantis
CategoryStudy Management
Description

Industry-leading GLP-compliant preclinical study management software covering data capture, analysis, and reporting for non-clinical evaluation studies including study design, dosing, observations, and clinical pathology.

8Morphit
CategoryStudy Management
Description

Data visualization tool enabling real-time interpretation and analysis of complex datasets, allowing researchers to make informed adjustments to study parameters quickly.

9Pristima
CategoryStudy Management
Description

Xybion Legacy study management software for preclinical research data management and compliance.

10BioRails
CategoryStudy Management
Description

Discovery solution optimizing bioanalysis workflows, integrating seamlessly with various stages of research to support collaborative, real-time data access for in vitro ADME/DMPK and in vivo PK studies.

11Comet Assay IV
CategoryStudy Management
Description

Image analysis system providing consistent and reliable comet assay scoring for genetic toxicology studies.

12Logbook
CategoryStudy Management
Description

Electronic Laboratory Notebook (ELN) providing digital alternative to traditional lab records, capturing study notes and observations in secure, accessible format with data traceability and compliance.

13NOTOCORD-hem
CategoryStudy Management
Description

Software platform for acquisition, analysis, and custom reporting of physiological signals with focus on Cardiovascular, Respiratory and Nervous System Research.

14Cyto Study Manager
CategoryStudy Management
Description

Specialized genetic toxicology data capture and reporting platform with templates and tools for accurate documentation meeting compliance requirements in genetox studies.

15SEND Advantage Services
CategoryRegulatory Submission
Description

Comprehensive managed services for SEND-compliant dataset generation including SEND Deliver, SEND Comply, SEND Advise, SEND Warehousing, and SEND Source programs.

16Submit
CategoryRegulatory Submission
Description

SEND submission management suite providing centralized data control, automated updates, version control, and streamlined management for regulatory filings including SENDirect, DefineNow, GuidePro, SEND checker, SEND editor, and SENDView.

17Matrix Gemini LIMS
CategoryLab Execution
Description

Configurable Laboratory Information Management System covering data collection, storage, and reporting while meeting global compliance and quality standards with modules including LIMS Express, LIMS Stability, and Web Portal.

18Accel
CategoryClinical Trial Analytics
Description

Cloud-based validated Statistical Computing Environment (SCE) providing scalable, compliant solution for data analysis and sharing with pre-configured biostats tools for streamlined collaboration.

19Aspire
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Extended 5-year Research Collaboration Agreement with U.S. FDA through February 2031, continuing a partnership established in 2011. The collaboration centers on the Leadscope platform to advance predictive toxicology models, expand curated safety databases, and enhance regulatory decision-support tools for drug safety assessments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Collaboration with FDA focuses on advancing predictive toxicology models, expanding curated safety databases, and enhancing regulatory decision-support tools. This extension reflects growing regulatory shift toward computational toxicology approaches and adoption of 3Rs principles to reduce animal testing.

Strategic tierCoreTypeOthersAnnounced on2025-12-02
Description

Acquisition of Autoscribe Informatics contributed to Instem's expanded footprint in R&D solutions as part of growth strategy.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-11-06
Description

Presented research at ELRIG Drug Discovery 2025 showcasing drug discovery platforms BioRails and Climb, with case studies demonstrating efficiency gains.

Strategic tierCoreTypeOthersAnnounced on2025-07-31
Description

Instem acquired all shares of Xybion from Banerjee Group LLC controlled by Dr. Pradip K. Banerjee, expanding Instem's preclinical study management capabilities.

Strategic tierCoreTypeOthersAnnounced on2025-01-01
Description

Acquired RockStep Solutions and its Climb platform to strengthen in vivo study management capabilities within Instem's portfolio.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-05-10
Description

Participated as part of a consortium led by Fraunhofer Institute in an EMA-funded research project investigating the mutagenicity of N-nitrosamines. Project aims to improve risk assessment and safety testing methods over a two-year period.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Public cloud-software leader for life sciences spanning clinical (Veeva Vault CTMS, EDC, eTMF), regulatory, quality, and commercial. Overlaps with Instem across clinical trial informatics, regulatory submissions, and quality management, but operates at much larger scale with a broader portfolio.

TypeBroad incumbent
Description

Oracle's Clinical One and safety/pharmacovigilance suites compete with Instem's clinical trial analytics (Accel, Aspire, Blur) and SEND/safety offerings. Broader enterprise footprint and deeper integration with Oracle's database and analytics stack differentiate it from Instem's specialized approach.

TypeBroad incumbent
Description

Provides scientific informatics for discovery, preclinical, regulatory, and quality in life sciences. Directly comparable to Instem's in silico (Leadscope), study management (Provantis, BioRails), and lab execution (Matrix Gemini LIMS) suites, though positioned as a horizontal scientific platform rather than a regulatory-focused specialist.

TypeDirect peer
Description

Life sciences R&D platform vendor with strong positions in pharmacovigilance/drug safety, regulatory affairs, and clinical trial master file management. Direct overlap with Instem's safety (Centrus), regulatory submission, and SEND/Submit capabilities, serving the same large-pharma and mid-pharma buyer base.

TypeDirect peer
Description

Biosimulation, regulatory science, and drug development services/software vendor. Comparable to Instem in modeling-and-simulation-driven drug development (analogous to Leadscope QSAR) and in regulatory submission support, with deeper reach into model-based regulatory dossiers.

TypeDirect peer
Description

Independent LIMS and ELN vendor with deep penetration in regulated laboratories. Direct competitor to Instem's Matrix Gemini LIMS and Logbook ELN, particularly in pharma quality control and stability labs where both vendors actively bid.

TypeDirect peer
Description

Scientific R&D informatics platform for discovery and development, including ELN, LIMS, biology, and chemistry applications. Comparable to Instem's study management and lab execution portfolio, with comparable focus on data integration across life sciences R&D workflows.

TypeBroad incumbent
Description

Signals Software (formerly PerkinElmer Informatics) provides TIBCO Spotfire-based analytics, LIMS, and ELN used by pharma discovery and translational labs. Competes with Instem's preclinical analytics, in silico, and LIMS offerings as part of a broader life sciences instrumentation and informatics portfolio.

TypeEmerging player
Description

Computational chemistry and predictive modeling platform increasingly applied to toxicology and drug safety. Overlaps with Instem's Leadscope QSAR/predictive toxicology franchise at the intersection of physics-based modeling and regulatory safety assessment.

TypeBroad incumbent
Description

Thermo Fisher's informatics LIMS offerings (SampleManager LIMS, Watson LIMS for bioanalysis) compete with Matrix Gemini LIMS and BioRails in regulated bioanalytical and QC lab settings. Strong incumbent in large pharma labs where Instem Catalyst and d-wise analytics often co-bid.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A14 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Instem

Life Sciences R&D Softwareinstem.com

Instem firmographics

Firmographics
Name
Instem
Legal name
Instem
Website
https://instem.com
Company type
Private
Founded year
1969
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Instem industry classification

Industry
Product category
Life Sciences R&D Software
NAICS
Professional, Scientific, and Technical Services (54), Other Scientific and Technical Consulting Services (54169), Computer Systems Design Services (541512), Management, Scientific, and Technical Consulting Services (5416)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700)
akta.pro primary industry
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
akta.pro secondary industries
Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB), Quality Assurance, GxP Compliance & Auditing FSP (HLAGAOAE), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

  • Preclinical study management
  • Regulatory submission software
  • Predictive toxicology software
  • Laboratory information systems
  • Clinical trial analytics

Where Instem is headquartered

Location

Headquarters

HQ city
Conshohocken
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Instem business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. SaaS Software Subscriptions: Instem generates revenue primarily through SaaS subscription licensing of its software platforms including Leadscope, Provantis, BioRails, Matrix Gemini LIMS, and Clinical Trial Analytics solutions. Annual and multi-year subscription contracts with enterprise customers.
  2. Professional Services: Instem Catalyst provides scientific and regulatory consulting services including strategy and advisory, implementation and modernization, validation and compliance, adoption and optimization, and resourcing/managed services.
  3. SEND Services: SEND Advantage Services including SEND Deliver, SEND Comply, SEND Advise, SEND Warehousing, and SEND Source for SEND data conversion and compliance services.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise SaaS subscription model

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Instem product offering

Product offering

Core offering

Instem is a global SaaS provider for life sciences R&D, offering an integrated portfolio spanning in silico & data insights (Leadscope predictive toxicology), preclinical study management (Provantis, BioRails, Climb), regulatory submission (SEND Advantage Services, Submit), lab execution (Matrix Gemini LIMS), and clinical trial analytics (Accel, Aspire, Blur via d-wise). The company sells subscription-based software platforms and supporting professional services to pharmaceutical, biotech, CRO, CDMO, academic, and agrichemical organizations across 700+ clients globally.

Product overview

Instem is a global SaaS provider for life sciences R&D offering an integrated platform of solutions across In Silico & Data Insights, Study Management, Regulatory Submission, Lab Execution, and Clinical Trial Analytics. The portfolio includes core products such as Leadscope Model Applier, Predict, KnowledgeScan, Centrus, and Advance for predictive toxicology and data insights; Provantis, BioRails, Climb, Morphit, and Pristima for study management; SEND Advantage Services and Submit for regulatory submissions; Matrix Gemini LIMS for lab execution; and Accel, Aspire, Blur, and CTT Services for clinical trial analytics through d-wise (an Instem company). The company serves over 700 clients including pharmaceutical, biotech, CRO, CDMO, academic research, and agrichemical organizations. Founded in 1969, Instem has grown through acquisitions including RockStep Solutions, Xybion, and Autoscribe Informatics.

Differentiator

Problem solved

Functional benefit

Brands

  • Leadscope: In silico predictive toxicology platform including Leadscope Model Applier, Predict, KnowledgeScan, Centrus, and Advance solutions
  • Provantis
  • Climb
  • BioRails
  • Matrix Gemini LIMS
  • Predict
  • KnowledgeScan
  • Centrus
  • Advance
  • Accel
  • Aspire
  • Blur
  • SEND Advantage
  • Submit

Products and services

  • Leadscope Model Applier Predictive QSAR modeling platform delivering accurate predictions for wide-ranging toxicological endpoints, driven by regulatory guidelines, enabling early risk assessments and reducing reliance on traditional animal testing.
  • Predict Expert In Silico toxicology support service delivering a wide range of reports with proven regulatory acceptance for early-stage safety assessments.
  • KnowledgeScan Technology-enabled Target Safety Assessment service that aggregates proprietary and public data, providing comprehensive insights into potential toxicological risks for faster data-driven decisions.
  • Centrus Advanced Translational Safety Solution enabling data alignment, review, and visualizations from diverse sources for high-quality data management and seamless data sharing.
  • Advance Expert-led S1B Weight of Evidence (WoE) assessment service evaluating carcinogenicity risks, supporting ICH S1B guidelines and accelerating development timelines.
  • Climb Cloud-based preclinical in vivo data capture platform enabling capture from any therapeutic area to accelerate studies, with 75% reduction in setup time demonstrated.
  • Provantis Industry-leading GLP-compliant preclinical study management software covering data capture, analysis, and reporting for non-clinical evaluation studies including study design, dosing, observations, and clinical pathology.
  • Morphit Data visualization tool enabling real-time interpretation and analysis of complex datasets, allowing researchers to make informed adjustments to study parameters quickly.
  • Pristima Xybion Legacy study management software for preclinical research data management and compliance.
  • BioRails Discovery solution optimizing bioanalysis workflows, integrating seamlessly with various stages of research to support collaborative, real-time data access for in vitro ADME/DMPK and in vivo PK studies.
  • Comet Assay IV Image analysis system providing consistent and reliable comet assay scoring for genetic toxicology studies.
  • Logbook Electronic Laboratory Notebook (ELN) providing digital alternative to traditional lab records, capturing study notes and observations in secure, accessible format with data traceability and compliance.
  • NOTOCORD-hem Software platform for acquisition, analysis, and custom reporting of physiological signals with focus on Cardiovascular, Respiratory and Nervous System Research.
  • Cyto Study Manager Specialized genetic toxicology data capture and reporting platform with templates and tools for accurate documentation meeting compliance requirements in genetox studies.
  • SEND Advantage Services Comprehensive managed services for SEND-compliant dataset generation including SEND Deliver, SEND Comply, SEND Advise, SEND Warehousing, and SEND Source programs.
  • Submit SEND submission management suite providing centralized data control, automated updates, version control, and streamlined management for regulatory filings including SENDirect, DefineNow, GuidePro, SEND checker, SEND editor, and SENDView.
  • Matrix Gemini LIMS Configurable Laboratory Information Management System covering data collection, storage, and reporting while meeting global compliance and quality standards with modules including LIMS Express, LIMS Stability, and Web Portal.
  • Accel Cloud-based validated Statistical Computing Environment (SCE) providing scalable, compliant solution for data analysis and sharing with pre-configured biostats tools for streamlined collaboration.
  • Aspire

Quantifiable outcome

  • 75% reduction in setup time and 45% reduction in study design time

Companies that use Instem

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Instem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Instem partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • U.S. FDAcoreStrategic or Co-development Partner · 19 March 2026Extended 5-year Research Collaboration Agreement with U.S. FDA through February 2031, continuing a partnership established in 2011. The collaboration centers on the Leadscope platform to advance predictive toxicology models, expand curated safety databases, and enhance regulatory decision-support tools for drug safety assessments.
  • U.S. FDAcoreStrategic or Co-development Partner · 19 March 2026Collaboration with FDA focuses on advancing predictive toxicology models, expanding curated safety databases, and enhancing regulatory decision-support tools. This extension reflects growing regulatory shift toward computational toxicology approaches and adoption of 3Rs principles to reduce animal testing.
  • Autoscribe Informatics (Acquisition)coreOthers · 2 December 2025Acquisition of Autoscribe Informatics contributed to Instem's expanded footprint in R&D solutions as part of growth strategy.
  • ELRIGminorGTM or Marketing Partner · 6 November 2025Presented research at ELRIG Drug Discovery 2025 showcasing drug discovery platforms BioRails and Climb, with case studies demonstrating efficiency gains.
  • Xybion (Acquisition)coreOthers · 31 July 2025Instem acquired all shares of Xybion from Banerjee Group LLC controlled by Dr. Pradip K. Banerjee, expanding Instem's preclinical study management capabilities.
  • RockStep Solutions (Acquisition)coreOthers · 1 January 2025Acquired RockStep Solutions and its Climb platform to strengthen in vivo study management capabilities within Instem's portfolio.
  • Fraunhofer InstituteminorStrategic or Co-development Partner · 10 May 2022Participated as part of a consortium led by Fraunhofer Institute in an EMA-funded research project investigating the mutagenicity of N-nitrosamines. Project aims to improve risk assessment and safety testing methods over a two-year period.

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Instem competitors and assessment

Company assessment

Broad incumbents

  • Veeva Systems: Public cloud-software leader for life sciences spanning clinical (Veeva Vault CTMS, EDC, eTMF), regulatory, quality, and commercial. Overlaps with Instem across clinical trial informatics, regulatory submissions, and quality management, but operates at much larger scale with a broader portfolio.
  • Oracle Health Sciences: Oracle's Clinical One and safety/pharmacovigilance suites compete with Instem's clinical trial analytics (Accel, Aspire, Blur) and SEND/safety offerings. Broader enterprise footprint and deeper integration with Oracle's database and analytics stack differentiate it from Instem's specialized approach.
  • Dassault Systèmes BIOVIA: Provides scientific informatics for discovery, preclinical, regulatory, and quality in life sciences. Directly comparable to Instem's in silico (Leadscope), study management (Provantis, BioRails), and lab execution (Matrix Gemini LIMS) suites, though positioned as a horizontal scientific platform rather than a regulatory-focused specialist.
  • Revvity Signals: Signals Software (formerly PerkinElmer Informatics) provides TIBCO Spotfire-based analytics, LIMS, and ELN used by pharma discovery and translational labs. Competes with Instem's preclinical analytics, in silico, and LIMS offerings as part of a broader life sciences instrumentation and informatics portfolio.
  • Thermo Fisher SampleManager / Watson LIMS: Thermo Fisher's informatics LIMS offerings (SampleManager LIMS, Watson LIMS for bioanalysis) compete with Matrix Gemini LIMS and BioRails in regulated bioanalytical and QC lab settings. Strong incumbent in large pharma labs where Instem Catalyst and d-wise analytics often co-bid.

Direct peers

  • ArisGlobal: Life sciences R&D platform vendor with strong positions in pharmacovigilance/drug safety, regulatory affairs, and clinical trial master file management. Direct overlap with Instem's safety (Centrus), regulatory submission, and SEND/Submit capabilities, serving the same large-pharma and mid-pharma buyer base.
  • Certara: Biosimulation, regulatory science, and drug development services/software vendor. Comparable to Instem in modeling-and-simulation-driven drug development (analogous to Leadscope QSAR) and in regulatory submission support, with deeper reach into model-based regulatory dossiers.
  • LabWare: Independent LIMS and ELN vendor with deep penetration in regulated laboratories. Direct competitor to Instem's Matrix Gemini LIMS and Logbook ELN, particularly in pharma quality control and stability labs where both vendors actively bid.
  • Dotmatics: Scientific R&D informatics platform for discovery and development, including ELN, LIMS, biology, and chemistry applications. Comparable to Instem's study management and lab execution portfolio, with comparable focus on data integration across life sciences R&D workflows.

Emerging players

  • Schrödinger: Computational chemistry and predictive modeling platform increasingly applied to toxicology and drug safety. Overlaps with Instem's Leadscope QSAR/predictive toxicology franchise at the intersection of physics-based modeling and regulatory safety assessment.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Instem social profiles

Digital presence

Instem compliance and trust

Trust signal

Compliance2 records

Instem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Instem leadership team

Management profile

Number of profiles

Profiles7 records

Instem subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Instem funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Instem M&A and investment

M&A and investment

M&A14 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instem

What does Instem do?

Instem is a global SaaS provider for life sciences R&D, offering an integrated portfolio spanning in silico & data insights (Leadscope predictive toxicology), preclinical study management (Provantis, BioRails, Climb), regulatory submission (SEND Advantage Services, Submit), lab execution (Matrix Gemini LIMS), and clinical trial analytics (Accel, Aspire, Blur via d-wise). The company sells subscription-based software platforms and supporting professional services to pharmaceutical, biotech, CRO, CDMO, academic, and agrichemical organizations across 700+ clients globally.

Is Instem a public or private company?

Instem is a private company. It is classified as public and is currently operating.

When was Instem founded?

Instem was founded in 1969. It employs 51 to 100 people.

Where is Instem based?

Instem is headquartered in Conshohocken, United States, in the North America region.

How does Instem make money?

Three revenue lines are on record. SaaS Software Subscriptions are the primary driver. The others are professional Services and SEND Services.

Who are Instem's main competitors?

Broad incumbents on record are Veeva Systems, Oracle Health Sciences, Dassault Systèmes BIOVIA, Revvity Signals and Thermo Fisher SampleManager / Watson LIMS. Direct peers are ArisGlobal, Certara, LabWare and Dotmatics. Schrödinger is listed as an emerging player.

Does Instem have an API?

No public API is recorded for Instem.

What industry is Instem in?

Instem's product category is Life Sciences R&D Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAGAOAB, Data Management, Biostatistics & Statistical Programming FSP. Its NAICS code is 54 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizd-wise Names Christine Oliver President to Lead Next Growth PhaseClinical technology provider d-wise, an Instem company, has appointed Christine Oliver, a two-time CEO with experience leading Beaconcure and endpoint Clinical, as president to lead its next phase of expansion in clinical trial analytics and statistical computing infrastructure. Oliver brings direct experience scaling specialized software businesses serving regulated life sciences customers, positioning d-wise to accelerate revenue growth and expand strategic customer relationships in a market where demand has risen for tools improving trial efficiency and reducing operational risk. The appointment reflects a broader shift in life sciences technology as pharmaceutical sponsors seek to modernize fragmented clinical development systems with automation and AI capabilities.Business Wire Blogd-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growthd-wise appointed Christine Oliver as President, bringing over two decades of clinical technology leadership, including CEO roles at Beaconcure and endpoint Clinical. The appointment follows the company's 2026 brand relaunch, with a focus on expanding strategic impact and accelerating growth.YahooINSTEM Announces Extension of Research Collaboration Agreement with U.S. FDA to 2031Instem, a global SaaS provider for life sciences R&D, announced a 5-year extension of its Research Collaboration Agreement with the U.S. FDA, continuing a partnership first established in 2011 through February 2031. The collaboration utilizes Instem's Leadscope platform to advance predictive toxicology models, expand curated safety databases, and enhance regulatory decision-support tools for drug safety assessments. This extension reflects the growing regulatory shift toward computational toxicology approaches and adoption of 3Rs principles to reduce animal testing in favor of alternative methods.PharmiWeb.comINSTEM Announces Extension of Research Collaboration Agreement with U.S. FDA to 2031Instem, a global SaaS provider for life sciences R&D, announced a 5-year extension of its Research Collaboration Agreement (RCA) with the U.S. FDA through February 2031, continuing a partnership that began in 2011. The collaboration centers on the Leadscope platform to advance predictive toxicology models, expand curated safety databases, and enhance regulatory decision-support tools for drug safety assessments. Instem CEO Vik Krishnan emphasized the company's commitment to staying at the forefront of regulatory developments to help clients bring life-changing therapies to market.Express PharmaReport maps non-animal testing methods for drug development in IndiaA multi-stakeholder report titled Landscape Analysis on Alternatives to Animal Testing for Drug Development in India has been released, co-developed by Humane World for Animals India, DBT-InSTEM, Animal Law and Policy Network, and Dr. Reddy's Laboratories Limited, outlining the role of Non-Animal Methods in pharmaceutical and MedTech research. The report maps opportunities for non-animal testing approaches such as organ-on-chip models and computational simulations, which currently face low predictive accuracy from traditional animal models where only about 10% of drugs entering Phase I trials receive regulatory approval. Released under India's Viksit Bharat vision targeting a USD 500 billion pharmaceutical sector by 2047, the report recommends forming an industry consortium, creating a central NAM agency, and establishing Centres of Excellence to accelerate adoption.MarketintellixIn-Depth Research on Computational Toxicology Solutions MarketMarket IntelliX published a market research report projecting the global Computational Toxicology Solutions market to grow from US$54.2 million in 2025 to US$98 million by 2031, representing a CAGR of 10.6% during the forecast period. The report identifies regulatory pressures from bodies such as EPA, FDA, and REACH, advancements in AI and machine learning, and cost-effectiveness compared to traditional in vivo testing as key market drivers. Key players analyzed include Instem (Leadscope), Lhasa Limited, MultiCASE, Inotiv, Simulations Plus Inc, Schrodinger, Aclaris, Evogene, Deciphex (Patholytix), and Exscientia across North America, Europe, Asia-Pacific, South America, and Middle East & Africa regions.PharmiWeb.comInstem Unveils New Global Headquarters in Boston, MAInstem, a global SaaS provider for life sciences R&D, officially opened its new global headquarters at the Prudential Center in Boston's Back Bay, marking a strategic relocation to one of the world's leading biotech innovation hubs. The company stated the move reflects its transformation focused on customer obsession, operational excellence, and accelerated growth supported by recent acquisitions including RockStep Solutions, Xybion, and Autoscribe Informatics. Founded in the United Kingdom in 1969 and owned by ARCHIMED since 2023, Instem's new Boston hub will serve as the central collaboration center for its North American and global operations.News-MedicalDriving scientific insight and efficiency in drug discoveryInstem, a UK-founded life sciences software company established in 1969, presented research at ELRIG Drug Discovery 2025 showcasing its drug discovery platforms BioRails and Climb, with case studies demonstrating significant efficiency gains including 75% reduction in setup time and 45% reduction in study design time. The company expanded its capabilities in 2025 by integrating RockStep Solutions and its Climb platform into its portfolio to strengthen in vivo study management. The poster highlights how integrated platforms can enhance data integrity, facilitate collaboration, and expedite drug development workflows.PR NewswirePreclinical Drug Discovery: Turning Drug Safety Data into Decisions, Upcoming Webinar Hosted by XtalksXtalks, a provider of educational webinars for the life science industry, is hosting a free webinar on October 16, 2025 focused on leveraging data-driven technologies in preclinical drug discovery to improve decision-making. The webinar will feature experts from Instem discussing regulatory frameworks including ICH S1B, ICH M7, and emerging ICH Q3E guidelines, along with applications such as toxicity profiling and lead compound selection. The session aims to address challenges organizations face in transforming preclinical data into meaningful insights that meet regulatory expectations for transparency and interpretability.InstemInstem Announces Acquisition of RockStep Solutions, Inc.Instem has completed the acquisition of RockStep Solutions, Inc., integrating its Climb cloud-based software with Instem's Provantis platform to create a unified solution for preclinical study management. This merger combines GLP and non-GLP capabilities, expanding Instem's portfolio to include vivarium management and data analytics for pharmaceutical, biotech, and CRO customers. The transaction aims to provide an end-to-end environment that reduces operational inefficiencies and supports the entire preclinical R&D lifecycle.